{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T02:23:55Z","timestamp":1785291835125,"version":"3.55.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/ http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:p>A boy with central nervous system relapse of Burkitt leukemia developed fever and neurologic symptoms and cognitive impairment. He had received multi-drug chemotherapy including rituximab. Enterovirus (EV) was detected in cerebrospinal fluid by polymerase chain reaction, and magnetic resonance imaging findings were consistent with viral infection. The patient was treated with intravenous immunoglobulin and within 1 month cleared his EV. Rituximab can cause a profound B-cell deficiency predisposing patients to infections including EV encephalitis. This is the first report of enteroviral encephalitis in a child undergoing treatment for lymphoma with rituximab and suggests the need to watch for this complication of therapy.<\/jats:p>","DOI":"10.1097\/mph.0000000000001077","type":"journal-article","created":{"date-parts":[[2018,1,9]],"date-time":"2018-01-09T22:27:58Z","timestamp":1515536878000},"page":"e27-e29","source":"Crossref","is-referenced-by-count":9,"title":["Enteroviral Encephalitis in a Child With CNS Relapse of Burkitt Leukemia Treated With Rituximab"],"prefix":"10.1097","volume":"41","author":[{"given":"Najma","family":"Shaheen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Mussai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"issue":"suppl 12","key":"R2-20230918","first-page":"99","article-title":"A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia","volume":"27","author":"Saleh","year":"2000","journal-title":"Semin Oncol"},{"key":"R3-20230918","article-title":"Results of the randomized Intergroup trial Inter-BNHL Ritux 2010 for children and adolescents with high-risk B-cell non-Hodgkin lymphoma and mature acute leukemia: Evaluation of rituximab efficacy in addition to standard LMB chemotherapy regimen (abstract)","author":"Minard-Colin","year":"2016","journal-title":"ASCO Annual Meeting"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2141.2010.08202.x","article-title":"Enteroviral meningoencephalitis as complication of Rituximab therapy in a patient treated for diffuse large B-cell lymphoma","volume":"150","author":"Servais","year":"2010","journal-title":"Br J Haematol"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood.V100.6.2257","article-title":"Rituximab treatment results in impaired secondary humoral immune responsiveness","volume":"100","author":"Van der Kolk","year":"2002","journal-title":"Blood"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jns.2011.03.009","article-title":"Enterovirus 71 meningoencephalitis complicating rituximab therapy","volume":"305","author":"Ahmed","year":"2011","journal-title":"J Neurol Sci"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2008.18.0182","article-title":"Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab","volume":"27","author":"Yeo","year":"2009","journal-title":"J Clin Oncol"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","article-title":"Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project","volume":"113","author":"Carson","year":"2009","journal-title":"Blood"},{"key":"R9-20230918","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s12185-008-0066-7","article-title":"Increased incidence of interstitial pneumonia by CHOP combined with rituximab","volume":"87","author":"Ennishi","year":"2008","journal-title":"Int J Hematol"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1365-2141.2009.07748.x","article-title":"Enterovirus infection of neuronal cells post-rituximab","volume":"146","author":"Kiani-Alikhan","year":"2009","journal-title":"Br J of Haematology"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1086\/345746","article-title":"Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment","volume":"36","author":"Quartier","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R12-20230918","first-page":"1345","article-title":"Fatal case of enterovirus 71 infection and rituximab therapy, France 2012","volume":"19","author":"Kasab","year":"2013","journal-title":"Emerg Infect Dis"},{"key":"R13-20230918","first-page":"221","article-title":"Enteroviral encephalitis in a patient with a marginal zone lymphoma treated with rituximab","volume":"68","author":"Schilthuizen","year":"2010","journal-title":"Neth J Med"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/00013542-199701000-00004","article-title":"Enteroviral infection in immune-compromised host","volume":"8","author":"Galama","year":"1997","journal-title":"Rev Med Microbiol"},{"key":"R15-20230918","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.virol.2010.12.014","article-title":"Enterovirus infections of the central nervous system review","volume":"411","author":"Rhoades","year":"2011","journal-title":"Virology"},{"key":"R16-20230918","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/10428190902782210","article-title":"Opportunistic enteroviral meningoencephalitis: an unusual treatable complication of rituximab therapy","volume":"50","author":"Ganjoo","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"R17-20230918","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1365-2257.2006.00751.x","article-title":"Enteroviral meningoencephalitis in a patient with non-Hodgkin's lymphoma treated previously with rituximab","volume":"28","author":"Padate","year":"2006","journal-title":"Clin Lab Haematol"},{"key":"R18-20230918","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.3201\/eid2109.150104","article-title":"Disseminated enteroviral infection associated with obinutuzumab","volume":"21","author":"Dendle","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"R19-20230918","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/BF00918150","article-title":"Chronic enteroviral meningoencephalitis in agammaglobulinemia: case report and literature review","volume":"12","author":"Misbah","year":"1992","journal-title":"J Clin Immunol"},{"key":"R20-20230918","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S1474-4422(10)70209-X","article-title":"Clinical features, diagnosis, and management of enterovirus 71","volume":"9","author":"Ooi","year":"2010","journal-title":"Lancet Neurol"},{"key":"R21-20230918","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1097\/00006454-198805001-00007","article-title":"Intraventricular gamma-globulin for the management of enterovirus encephalitis","volume":"7","author":"Dwyer","year":"1988","journal-title":"Pediatr Infect Dis"},{"key":"R22-20230918","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S1286-4579(02)00008-4","article-title":"Implications of high RNA virus mutation rates: lethal mutagenesis and the antiviral drug ribavirin","volume":"4","author":"Crotty","year":"2002","journal-title":"Microbes Infect"},{"key":"R23-20230918","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.antiviral.2008.09.002","article-title":"New pleconaril and [(biphenyloxy)propyl]isoxazole derivatives with substitutions in the central ring exhibit antiviral activity against pleconaril-resistant coxsackievirus B3","volume":"81","author":"Schmidtke","year":"2009","journal-title":"Antiviral Res"},{"key":"R24-20230918","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1423-0127-21-14","article-title":"Recent developments in antiviral agents against enterovirus 71 infection","volume":"21","author":"Tan","year":"2014","journal-title":"J Biomed Sci"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00043426-201901000-00027","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T04:41:45Z","timestamp":1695012105000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-201901000-00027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000001077","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}